After our analysis, our patient’s list of 17 clinical/preclinical targets was refined to 3 top druggable pathways active in the patient’s tumor clusters: TFRC, NRP1, and EGFR. Of note, NRP1 is a SARS-CoV2 receptor, for which dozens of new drugs have recently been developed38,39, and hence may justify further clinical applicability in cancer. The gene discussed is TFRC; the disease is cancer.